**5. Conclusions**

Altogether, these results highlight that the newly developed nanocarriers can constitute a new therapeutic tool for treating NDs. The DHAH-NLCs were similar to previously developed NLCs in size, PDI, zeta values and TEM morphology. Moreover, they exhibited neuroprotective effects in a cell culture model of dopaminergic neurons and antiinflammatory properties, decreasing proinflammatory cytokine levels in primary microglia cell cultures. Although future studies are needed to check its suitability in a different cell culture model or animal model of the disease, the results presented in this research article are promising for this new functional nanocarrier. Moreover, the combination of this new, safe and effective nanocarrier with different clinically approved or investigated therapeutic molecules could become in an emerging tool to treat, in a synergistic manner, the symptoms associated with NDs.

**Author Contributions:** Conceptualization, S.H., E.H., M.I. and R.M.H.; writing—original draft preparation, S.H.; writing—review and editing, S.H., E.H., M.I. and R.M.H.; visualization, S.H.; supervision, E.H., M.I. and R.M.H.; project administration, E.H., M.I. and R.M.H.; funding acquisition, M.I. and R.M.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This project was partially supported by the Spanish Ministry of Economy and Competitiveness (RTC-2015-3542-1) and the Basque Government (Consolidated Groups, IT 907-16).

**Acknowledgments:** The authors give thanks for the technical and human support provided by SGIker of UPV/EHU and European funding (ERDF and ESF). S. Hernando thanks the Basque Government for the fellowship grant. *Pharmaceutics* **2020**, *12*, x 19 of 23

*Pharmaceutics* **2020**, *12*, x 19 of 23

**Conflicts of Interest:** The authors declare no conflict of interest. **Appendix A** 
